# A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

> **NCT00835380** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 80 (actual)

## Conditions studied

- Hepatitis A Virus Infection

## Interventions

- **BIOLOGICAL:** Hepatitis A Vaccine, Purified Inactivated (VAQTA™)

## Key facts

- **NCT ID:** NCT00835380
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835380, "A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00835380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*